| Business Summary | | Deltagen
Inc.
is
a
provider
of
genomics-based
information,
products
and
programs
that
are
used
to
discover
drug
targets
and
drug
candidates,
and
to
accelerate
pharmaceutical
and
biotechnology
drug
and
product
development.
The
Company
researches,
develops
and
uses
technologies
that
build
upon
its
technology
platforms
to
discover
the
function,
role,
usefulness
and
disease
relevance
of
mammalian
genes
and
secreted
proteins
in
drug
discovery
and
development.
The
Company
has
developed
and
plans
to
continue
to
develop
technologies,
products
and
programs
that
determine
the
function
and
disease
relevance
of
genes
in
mammalian
organisms. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Deltagen
Inc.
develops
technology
that
converts
raw
genetic
data
into
mammalian
gene
function
information
to
help
pharmaceutical
and
biotechnology
companies
expedite
the
drug
discovery
process.
For
the
six
months
ended
6/30/01,
sales
rose
from
$554
thousand
to
$5.2
million.
Net
loss
applicable
to
Common
fell
51%
to
$18.9
million.
Revenues
reflect
higher
sales
from
the
DeltaBase
mammalian
gene
function
database.
Lower
loss
reflects
the
absence
of
$22.4
million
in
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| William Matthews, Ph.D., 46 Pres,
CEO, Director | $318K | -- | Richard Hawkins CFO | -- | -- | Augustine Yee VP
of Corp. Devel., Gen. Counsel and Sec. | 236K | $288K | Kay Slocum VP of HR | -- | -- | John Burke, 39 VP
of Intellectual Property | 228K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|